Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Synta Pharmaceuticals Corp.

Criteria

Inclusion Criteria:

• Patients must be documented to be refractory or not candidates for current approved therapies.

• Must have an ECOG status 0-2.

• Peripheral neuropathy < or = 2.

• Must have acceptable organ and marrow function per protocol parameters.

• No clinically significant ventricular arrythmias or ischemia.

Exclusion Criteria:

• Must not be pregnant or breastfeeding.

• Chemotherapy or radiation within 3 weeks.

• Previous radiation to >25% of total bone marrow.

• Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation.

• Primary brain tumors or active brain metastases.

• Use of any investigational agents within 4 weeks.

• Treatment with chronic immunosuppressants.

• Uncontrolled, intercurrent illness.